2月14日，药明康德盘中上涨5.07%，截至11:18，报59.74元/股，成交23.9亿元，换手率1.63%，总市值1725.29亿元。
资料显示，无锡药明康德新药开发股份有限公司位于江苏省无锡市滨湖区马山五号桥，公司主要为全球生物医药行业提供一体化、端到端的新药研发和生产服务，业务涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。2022年，公司被MSCI评为ESG(环境、社会及管治)AA级，目前的赋能平台承载着来自全球30多个国家的6000多家合作伙伴的研发创新项目。
截至9月30日，药明康德股东户数38.5万，人均流通股7562股。
2024年1月-9月，药明康德实现营业收入277.02亿元，同比减少6.23%；归属净利润65.33亿元，同比减少19.11%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.